Join our daily newsletter At The Bell to receive exclusive market insights
- Chimeric Therapeutics’ (CHM) Chief Operating Officer takes the reins as Chief Executive Officer and Managing Director
- Jennifer Chow will receive a total fixed remuneration of US$550,000 (A$753,000) in her new role, with incentives issued at performance milestones
- Ms Chow brings more than 20 years of commercial strategy and marketing experience to the role which will support CHM’s development plans
- Chimeric Therapeutics last traded in the grey at 31.5 cents
Chimeric Therapeutics (CHM) has seen its Chief Operating Officer take the reins as Chief Executive Officer and Managing Director.
Current COO, Jennifer Chow, will receive a total fixed remuneration of US$550,000 (A$$753,000) in her new role, with incentives issued once performance milestones have been ticked off.
Jennifer Chow has been in the role since November 2020, before which she was Head of Global Marketing, Analytics and Commercial Operations at global CAR T company, Kite Pharmaceuticals.
Ms Chow comes with more than 20 years of commercial strategy and marketing experience, focused on cellular therapy, hematology and oncology.
Furthermore, her appointment will support the company’s plan to develop its oncology pipeline with new and novel cell therapy assets for cancer patients.
Executive Chairman of Chimeric Therapeutics, Paul Hopper, said the company was delighted to appoint Ms Chow as MD and CEO.
“During her time with Chimeric thus far as COO, Jennifer has demonstrated outstanding dedication and leadership while importantly proving to be exceedingly knowledgeable in the field of cell therapy,” Mr Hopper said.
“The team we’ve been able to assemble at Chimeric brings deep scientific and commercial cell therapy expertise to the business and gives us great confidence moving forward under Jenn’s leadership.”
Chimeric Therapeutics was trading in the grey at 31.5 cents at 2:15 pm AEST.
